Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis

Saved in:
Bibliographic Details
Published in:British journal of haematology 2016-06, Vol.173 (6), p.938-940
Main Authors: Guglielmelli, Paola, Rotunno, Giada, Bogani, Costanza, Mannarelli, Carmela, Giunti, Laura, Provenzano, Aldesia, Giglio, Sabrina, Squires, Matthew, Stalbovskaya, Viktoriya, Gopalakrishna, Prashanth, Vannucchi, Alessandro M.
Format: Article
Language:English
Subjects:
CALR
Calreticulin - genetics
Humans
JAK inhibitor
myelofibrosis
myeloproliferative neoplasm
Primary Myelofibrosis - drug therapy
Primary Myelofibrosis - genetics
Primary Myelofibrosis - mortality
Pyrazoles - administration & dosage
Retrospective Studies
ruxolitinib
Splenomegaly - drug therapy
Survival Rate
Thrombocytosis - drug therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.13644